El-Serag H.B. Sweet S. Winchester C.C. et al.

Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review.

Gut. 63: 871-880Vakil N. van Zanten S.V. Kahrilas P. et al.

The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus.

Am J Gastroenterol. 101 (): 1900-1920

Extraesophageal manifestations of gastroesophageal reflux disease.

Gastroenterol Clin North Am. 42: 71-91Tack J. Becher A. Mulligan C. et al.

Systematic review: the burden of disruptive gastro-oesophageal reflux disease on health-related quality of life.

Aliment Pharmacol Ther. 35: 1257-1266Camilleri M. Dubois D. Coulie B. et al.

Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study.

Clin Gastroenterol Hepatol. 3: 543-552Nilsson M. Johnsen R. Ye W. et al.

Prevalence of gastro-oesophageal reflux symptoms and the influence of age and sex.

Scand J Gastroenterol. 39: 1040-1045Eusebi L.H. Ratnakumaran R. Yuan Y. et al.

Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis.

Gut. 67: 430-440Lin M. Gerson L.B. Lascar R. et al.

Features of gastroesophageal reflux disease in women.

Am J Gastroenterol. 99: 1442-1447Mittal R.K. McCallum R.W.

Characteristics and frequency of transient relaxations of the lower esophageal sphincter in patients with reflux esophagitis.

Gastroenterology. 95: 593-599De Giorgi F. Palmiero M. Esposito I. et al.

Pathophysiology of gastro-oesophageal reflux disease.

Acta Otorhinolaryngol Ital. 26: 241-246Diener U. Patti M.G. Molena D. et al.

Esophageal dysmotility and gastroesophageal reflux disease.

J Gastrointest Surg. 5: 260-265Patti M.G. Goldberg H.I. Arcerito M. et al.

Hiatal hernia size affects lower esophageal sphincter function, esophageal acid exposure, and the degree of mucosal injury.

Am J Surg. 171: 182-186Katz P.O. Dunbar K.B. Schnoll-Sussman F.H. et al.

ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease.

Am J Gastroenterol. 117: 27-56Zhang J.X. Ji M.Y. Song J. et al.

Proton pump inhibitor for non-erosive reflux disease: a meta-analysis.

World J Gastroenterol. 19: 8408-8419Khan M. Santana J. Donnellan C. et al.

Medical treatments in the short term management of reflux oesophagitis.

Cochrane Database Syst Rev. 2: CD003244

Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome.

Gastroenterology. 118: S9-S31

Acid suppression for reflux disease: "off-the-peg" or a tailored approach?.

Clin Gastroenterol Hepatol. 10: 210-213Mizunashi K. Furukawa Y. Katano K. et al.

Effect of omeprazole, an inhibitor of H+,K(+)-ATPase, on bone resorption in humans.

Calcif Tissue Int. 53: 21-25Waldum H.L. Sordal O. Fossmark R.

Proton pump inhibitors (PPIs) may cause gastric cancer - clinical consequences.

Scand J Gastroenterol. 53: 639-642

Long-term use of proton pump inhibitors as a risk factor for various adverse manifestations.

Therapie. 76: 13-21Gyawali C.P. Kahrilas P.J. Savarino E. et al.

Modern diagnosis of GERD: the Lyon Consensus.

Gut. 67: 1351-1362Yadlapati R. Kahrilas P.J. Fox M.R. et al.

Esophageal motility disorders on high-resolution manometry: Chicago classification version 4.0((c)).

Neuro Gastroenterol Motil. 33: e14058Roman S. Gyawali C.P. Savarino E. et al.

Ambulatory reflux monitoring for diagnosis of gastro-esophageal reflux disease: Update of the Porto consensus and recommendations from an international consensus group.

Neuro Gastroenterol Motil. 29: 1-15Neto R.M.L. Herbella F.A.M. Schlottmann F. et al.

Does DeMeester score still define GERD?.

Dis Esophagus. 32: doy118So J.B. Zeitels S.M. Rattner D.W.

Outcomes of atypical symptoms attributed to gastroesophageal reflux treated by laparoscopic fundoplication.

Surgery. 124: 28-32

Nonulcer dyspepsia: what it is and what it is not.

Mayo Clin Proc. 74 (): 1011-1014Kim M.S. Holloway R.H. Dent J. et al.

Radiofrequency energy delivery to the gastric cardia inhibits triggering of transient lower esophageal sphincter relaxation and gastroesophageal reflux in dogs.

Gastrointest Endosc. 57: 17-22Tam W.C. Schoeman M.N. Zhang Q. et al.

Delivery of radiofrequency energy to the lower oesophageal sphincter and gastric cardia inhibits transient lower oesophageal sphincter relaxations and gastro-oesophageal reflux in patients with reflux disease.

Gut. 52: 479-485Noar M. Squires P. Noar E. et al.

Long-term maintenance effect of radiofrequency energy delivery for refractory GERD: a decade later.

Surg Endosc. 28: 2323-2333Ma L. Li T. Liu G. et al.

STRETTA radiofrequency treatment vs Toupet fundoplication for gastroesophageal reflux disease: a comparative study.

BMC Gastroenterol. 20: 162Yan C. Liang W.T. Wang Z.G. et al.

Comparison of STRETTA procedure and toupet fundoplication for gastroesophageal reflux disease-related extra-esophageal symptoms.

World J Gastroenterol. 21: 12882-12887Liang W.T. Wu J.M. Hu Z.W. et al.

Laparoscopic Nissen fundoplication is more effective in treating patients with GERD-related chronic cough than STRETTA radiofrequency.

Minerva Chir. 69: 121-127Das B. Reddy M. Khan O.A.

Is the STRETTA procedure as effective as the best medical and surgical treatments for gastro-oesophageal reflux disease? A best evidence topic.

Int J Surg. 30: 19-24

The evolution of TIF: transoral incisionless fundoplication.

Therap Adv Gastroenterol. 13 ()Testoni P.A. Testoni S. Distefano G. et al.

Transoral incisionless fundoplication with EsophyX for gastroesophageal reflux disease: clinical efficacy is maintained up to 10 years.

Endosc Int Open. 7: E647-E654Wendling M.R. Melvin W.S. Perry K.A.

Impact of transoral incisionless fundoplication (TIF) on subjective and objective GERD indices: a systematic review of the published literature.

Surg Endosc. 27: 3754-3761Hopkins J. Switzer N.J. Karmali S.

Update on novel endoscopic therapies to treat gastroesophageal reflux disease: A review.

World J Gastrointest Endosc. 7: 1039-1044Richter J.E. Kumar A. Lipka S. et al.

Efficacy of Laparoscopic Nissen Fundoplication vs Transoral Incisionless Fundoplication or Proton Pump Inhibitors in Patients With Gastroesophageal Reflux Disease: A Systematic Review and Network Meta-analysis.

Gastroenterology. 154: 1298-12308 e7Testoni P.A. Testoni S. Mazzoleni G. et al.

Long-term efficacy of transoral incisionless fundoplication with Esophyx (Tif 2.0) and factors affecting outcomes in GERD patients followed for up to 6 years: a prospective single-center study.

Surg Endosc. 29: 2770-2780Trad K.S. Barnes W.E. Simoni G. et al.

Transoral incisionless fundoplication effective in eliminating GERD symptoms in partial responders to proton pump inhibitor therapy at 6 months: the TEMPO Randomized Clinical Trial.

Surg Innov. 22: 26-40Hunter J.G. Kahrilas P.J. Bell R.C. et al.

Efficacy of transoral fundoplication vs omeprazole for treatment of regurgitation in a randomized controlled trial.

Gastroenterology. 148: 324-333 e5Hakansson B. Montgomery M. Cadiere G.B. et al.

Randomised clinical trial: transoral incisionless fundoplication vs. sham intervention to control chronic GERD.

Aliment Pharmacol Ther. 42: 1261-1270Stefanidis G. Viazis N. Kotsikoros N. et al.

Long-term benefit of transoral incisionless fundoplication using the esophyx device for the management of gastroesophageal reflux disease responsive to medical therapy.

Dis Esophagus. 30: 1-8Trad K.S. Barnes W.E. Prevou E.R. et al.

The TEMPO Trial at 5 Years: Transoral Fundoplication (TIF 2.0) Is Safe, Durable, and Cost-effective.

Surg Innov. 25: 149-157

Transoral rotational esophagogastric fundoplication: technical, anatomical, and safety considerations.

Surg Endosc. 25: 2387-2399

Transoral Incisionless Fundoplication for Refractory Gastroesophageal Reflux Disease: Where Do We Stand?.

Clin Endosc. 49: 147-156